Omega Therapeutics, Inc. (OMGA) News
Filter OMGA News Items
OMGA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OMGA News Highlights
- For OMGA, its 30 day story count is now at 4.
- Over the past 27 days, the trend for OMGA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about OMGA are MRNA and CELL.
Latest OMGA News From Around the Web
Below are the latest news stories about OMEGA THERAPEUTICS INC that investors may wish to consider to help them evaluate OMGA as an investment opportunity.
Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET. The webcast will feature members of Omega’s leadershi |
Omega Therapeutics to Participate in Two Upcoming Investor ConferencesCAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that members of management will participate in fireside chats at two upcoming investor conferences. Jefferies Cell & Genetic Medicine Summit Date: Wednesday, September 27, 2023Time: 8:00 a.m. ET Chardan's 7th Annual Genetic Medicines ConferenceDate: Tuesda |
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerFlagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corp |
Omega Therapeutics Announces Updates to its Board of DirectorsChris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed to Board of Directors CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that Chris Schade has been appointed as Chairman of the Board, succeeding Noubar Afeyan, Ph.D. In additi |
Omega Therapeutics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsOmega Therapeutics ( NASDAQ:OMGA ) Second Quarter 2023 Results Key Financial Results Net loss: US$29.7m (loss widened... |
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue EstimatesOmega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -5.88% and 21.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressContinued Enrollment in Monotherapy Dose Escalation Stage of Phase 1/2 MYCHELANGELO™ I Study; Preliminary First-in-Human Safety, Tolerability, Pharmacologic and Translational Data Anticipated in the Fourth Quarter of 2023Presented New Preclinical Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting Demonstrating the Potential of MYC-targeting Omega Epigenomic Controllers™ to Synergize with Immunotherapies Further Strengthened Board of Directors with Appointment of Chris S |
Recursion (RXRX) Stock Surges 191% in 3 Months: Here's WhyRecursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development. |
Corcept's (CORT) Early-Stage Study on NASH Reveals Positive DataCorcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data. |
Omega Therapeutics Appoints Chris Schade to its Board of DirectorsAccomplished Industry Veteran Brings Deep Strategic and Operational ExpertiseCAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Chris Schade to its Board of Directors. Mr. Schade brings over 30 years of experience across the biopharma industry to support the Company’s long-term growth obj |